Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-βlb

Multiple Sclerosis

Volumn 16, Issue 7, 2010, Pages 801-809

  Alexander, J S ^a   Harris, M K ^a   Wells, S R ^a   Mills, G ^a   Chalamidas, K ^a   Ganta, V C ^a   McGee, J ^a   Jennings, M H ^a   Gonzalez Toledo, E ^a   Minagar, A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

IL 12; IL 17; IL 23; interferon 1b; MMP 8; MMP 9; multiple sclerosis; TIMP 1

Indexed keywords

GELATINASE B; INTERFERON BETA SERINE; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 23; METHYLPREDNISOLONE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BETA INTERFERON; BIOLOGICAL MARKER; IL12B PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MMP8 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; RELAPSE; BLOOD; CASE CONTROL STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; IMMUNOLOGY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKIN-23; LOUISIANA; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955022345     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510370791     Document Type: Article

References (56)

1. Frohman EM, Racke MK, Raine CS Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 2006 ; 354: 942-955.
2. Noseworthy JH, Lucchinetti C., Rodriguez M., Weinshenker BG Multiple sclerosis. N Engl J Med 2000 ; 343: 938-952.
3. Waxman SG Demyelinating diseases - new pathological insights, new therapeutic targets. N Engl J Med 1998 ; 338: 323-325.
4. Trapp BD, Peterson J., Ransohoff RM, Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 ; 338: 278-285.
5. Alexander JS, Elrod JW Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002 ; 200: 561-574.
6. Ram M., Sherer Y., Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006 ; 26: 299-307.
7. Stuve O., Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996 ; 40: 853-863.
8. Leppert D., Waubant E., Burk MR, Oksenberg JR, Hauser SL Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996 ; 40: 846-852.
9. Nelissen I., Martens E., Van den Steen PE, Proost P., Ronsse I., Opdenakker G. Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy. Brain 2003 ; 126: 1371-1381.
10. Candelario-Jalil E., Yang Y., Rosenberg GA Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009 ; 158: 983-994.
11. Stetler-Stevenson WG Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008 ; 1: re6.
12. Galboiz Y., Shapiro S., Lahat N., Rawashdeh H., Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001 ; 50: 443-451.
13. Waubant E., Goodkin DE, Gee L., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999 ; 53: 1397-1401.
14. Dressel A., Mirowska-Guzel D., Gerlach C., Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol Scand 2007 ; 116: 164-168.
15. Lima XT, Abuabara K., Kimball AB, Lima HC Briakinumab. Expert Opin Biol Ther 2009 ; 9: 1107-1113.
16. Longbrake EE, Racke MK Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis ? Expert Rev Neurother 2009 ; 9: 319-321.
17. Segal BM, Constantinescu CS, Raychaudhuri A., Kim L., Fidelus-Gort R., Kasper LH Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008 ; 7: 796-804.
18. Mondal S., Roy A., Pahan K. Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 2009 ; 182: 5013-5023.
19. Braitch M., Nunan R., Niepel G., Edwards LJ, Constantinescu CS Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol 2008 ; 65: 633-635.
20. Zabad RK, Metz LM, Todoruk TR, et al. The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study. Mult Scler 2007 ; 13: 517-526.
21. Correale J., Fiol M., Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 2006 ; 67: 652-659.
22. Gately MK, Renzetti LM, Magram J., et al. The interleukin-12/interleukin- 12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998 ; 16: 495-521.
23. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 ; 13: 715-725.
24. Khademi M., Bornsen L., Rafatnia F., et al. The effects of natalizumab on inflammatory mediators in multiple s28-36.clerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009 ; 16: 5.
25. Langrish CL, Chen Y., Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 ; 201: 233-240.
26. Weaver CT, Hatton RD, Mangan PR, Harrington LE IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007 ; 25: 821-852.
27. Matusevicius D., Kivisakk P., He B., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999 ; 5: 101-104.
28. McDonald WI Relapse, remission, and progression in multiple sclerosis. N Engl J Med 2000 ; 343: 1486-1487.
29. Poser CM, Paty DW, Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983 ; 13: 227-231.
30. Folgueras AR, Fueyo A., Garcia-Suarez O., et al. Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem 2008 ; 283: 9465-9474.
31. Galboiz Y., Shapiro S., Lahat N., Miller A. Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol 2002 ; 131: 191-200.
32. Avolio C., Filippi M., Tortorella C., et al. Serum MMP-9/ TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005 ; 11: 441-446.
33. Thorne M., Moore CS, Robertson GS Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol 2009 ; 211: 92-100.
34. Trojano M., Avolio C., Liuzzi GM, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999 ; 53: 1402-1408.
35. Minagar A., Alexander JS, Schwendimann RN, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008 ; 65: 199-204.
36. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008 ; 172: 146-155.
37. Matusevicius D., Kivisakk P., He B., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999 ; 5: 101-104.
38. Hedegaard CJ, Krakauer M., Bendtzen K., Lund H., Sellebjerg F., Nielsen CH T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 2008 ; 125: 161-169.
39. Liu M., Hu X., Wang Y., et al. Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta Neurol Scand 2009 ; 120: 235-241.
40. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009 ; 11: 625-630.
41. Ramgolam VS, Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J Immunol 2009 ; 183: 5418-5427.
42. Liu M., Hu X., Wang Y., et al. Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta Neurol Scand 2009 ; 120: 235-241.
43. Durelli L., Conti L., Clerico M., et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009 ; 65: 499-509.
44. Siegemund S., Schutze N., Freudenberg MA, Lutz MB, Straubinger RK, Alber G. Production of IL-12, IL-23 and IL-27p28 by bone marrow-derived conventional dendritic cells rather than macrophages after LPS/TLR4-dependent induction by Salmonella enteritidis. Immunobiology 2007 ; 212: 739-750.
45. Chung F. Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediators Inflamm 2001 ; 10: 51-59.
46. Rohowsky-Kochan C., Molinaro D., Choudhry A., Kahn M., Cook SD Impaired interleukin-12 production in multiple sclerosis patients. Mult Scler 1999 ; 5: 327-334.
47. Mannon P., Fuss I., Mayer L. Anti-interleukin-12 treats active Crohngs disease. Gastroenterology 2004 ; 126: A - 22.
48. Mannon PJ, Fuss IJ, Mayer L., Elson CO, Sandborn WJ, Present D., et al. Anti-interleukin-12 antibody for active Crohngs disease. N Engl J Med 2004 ; 351: 2069-2079.
49. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohngs disease. Gastroenterology 2008 ; 135: 1130-1141.
50. Longbrake EE, Racke MK Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis ? Expert Rev Neurother 2009 ; 9: 319-321.
51. Rentzos M., Nikolaou C., Rombos A., et al. Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse. Clin Neurol Neurosurg 2008 ; 110: 992-996.
52. Naseer T., Minshall EM, Leung DY, et al. Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997 ; 155: 845-851. (Pubitemid 27133392)
53. Fahey AJ, Robins RA, Kindle KB, Heery DM, Constantinescu CS Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. J Leukoc Biol 2006 ; 80: 133-144.
54. Yang, K., Wen, J., Liu, X., et al. Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-3 in Vogt-Koyanagi-Harada patients. Br J Ophthalmol 2009 ; 93: 249-253.
55. Rosenberg GA, Dencoff JE, Correa Jr N., Reiners M., Ford CC Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996 ; 46: 1626-1632.
56. Avolio C., Ruggieri M., Giuliani F., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003 ; 136: 46-53.